Research Article
Hsa_circ_0000190 Promotes NSCLC Cell Resistance to Cisplatin via the Modulation of the miR-1253/IL-6 Axis
Table 1
Relationship between hsa_circ_0000190 and clinicopathological data of NSCLC patients.
| Clinical feature | Low hsa_circ_0000190 | High hsa_circ_0000190 | P |
| Age (years) | 0.241 | <55 | 25 | 21 | | ≥55 | 43 | 47 | | Sex | 0.185 | Male | 35 | 37 | | Female | 33 | 31 | | TNM stage | <0.05 | I–II | 45 | 20 | | III–IV | 23 | 48 | | Tumor size | <0.05 | <5 cm | 42 | 21 | | ≥5 cm | 26 | 47 | | Metastasis | 0.091 | No | 33 | 31 | | Yes | 35 | 37 | |
|
|